Stock LRMR LARIMAR THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Analyst Reco. Larimar Therapeutics, Inc.

Equities

LRMR

US5171251003

Real-time Estimate Cboe BZX
Other stock markets
 11:46:02 2024-07-11 am EDT 		5-day change 1st Jan Change
9.595 USD +4.81% Intraday chart for Larimar Therapeutics, Inc. +26.09% +110.33%
Jul. 01 Larimar Therapeutics, Inc.(NasdaqGM:LRMR) dropped from Russell 3000E Value Index CI
Jul. 01 Larimar Therapeutics, Inc.(NasdaqGM:LRMR) added to Russell Microcap Growth Index CI

Analyst Reco.

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Guggenheim Adjusts Price Target on Larimar Therapeutics to $25 From $14, Maintains Buy Rating
MT
Citigroup Adjusts Price Target on Larimar Therapeutics to $10 From $4.50, Maintains Buy Rating
MT
JMP Securities Adjusts Price Target on Larimar Therapeutics to $25 From $17, Maintains Market Outperform Rating
MT
Citigroup Upgrades Larimar Therapeutics to Buy From Neutral, Price Target is $4.50
MT
Citigroup Cuts Larimar Therapeutics' Price Target to $4.50 From $7, Maintains Neutral Rating
MT
Guggenheim Adjusts Larimar Therapeutics' Price Target to $14 From $12, Keeps Buy Rating
MT
Citigroup Initiates Larimar Therapeutics at Neutral Rating
MT
Guggenheim Starts Larimar Therapeutics at Buy With $12 Price Target
MT
JMP Securities Adjusts Larimar Therapeutics' Price Target to $16 from $10, Maintains Market Outperform Rating
MT
William Blair Upgrades Larimar Therapeutics to Outperform From Market Perform
MT
JMP Securities Adjusts Larimar Therapeutics' Price Target to $8 From $30, Maintains Market Outperform Rating
MT
William Blair Downgrades Larimar Therapeutics to Market Perform From Outperform
MT
LARIMAR THERAPEUTICS : JMP Securities Adjusts Price Target on Larimar Therapeutics to $30 From $43, Maintains Market Outperform Rating
MT
LARIMAR THERAPEUTICS : JMP Securities Starts Larimar Therapeutics at Market Outperform with $35 Price Target
MT
LARIMAR THERAPEUTICS : William Blair Initiates Coverage on Larimar Therapeutics With Outperform Rating
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. LRMR Stock
  4. News Larimar Therapeutics, Inc.
  5. Analyst Reco.